Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01000740
First received: September 7, 2009
Last updated: May 20, 2010
Last verified: May 2010
  Purpose

The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.


Condition Intervention Phase
Non-small Cell Lung Cancer
Genetic: EGFR Mutation Test
Genetic: Ki-67 protein expression
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Describe the quality of life of long-term survivors who are not terminated from the EAP [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To describe the current tumour control status via RECIST [ Designated as safety issue: Yes ]
  • To collect the risk factors related to prognosis in addition to the information already collected from EAP (age, gender, histology, smoking history, previous history of anti-cancer treatment, disease stage before starting gefitinib treatment, etc.) [ Designated as safety issue: Yes ]
  • To describe the treatment compliance of gefitinib in these patients [ Designated as safety issue: Yes ]
  • To describe the current clinical status of long-term survivors in the EAP program by clinical [ Designated as safety issue: Yes ]
  • To compare the key clinical features (age group, gender, histology, smoking history, disease stage, treatment-naive or pre-treated, response to prior chemotherapy,) in fast-progressors versus long-term survivals. [ Designated as safety issue: Yes ]

Enrollment: 59
Study Start Date: August 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
Genetic: EGFR Mutation Test
Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
Genetic: Ki-67 protein expression
Ki-67 protein expression in tissue will be analysed by IHC method.
No Intervention: 2
Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
No Intervention: 3
Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures.
  • Participated in the Iressa EAP in China.
  • Diagnosed as NSCLC.
  • Patients who started EAP at least 3 years before this study initiated and have not yet terminated from the EAP (active long-term survivors).
  • Patients who consent to provide blood sample and available archival tumour tissue sample for EGFR gene testing (provision of tumour tissue sample is optional).

Exclusion Criteria:

  • Patients who disagree to participate this study.
  • Patients in whose medical objection was recorded to use the existing data from medical practice for scientific research.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01000740

Locations
China, Beijing
Research Site
Beijing, Beijing, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Jiangsu
Research Site
Nanjing, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
China, Shandong
Research Site
Jinan, Shandong, China
China, Shanghai
Research Site
Shanghai, Shanghai, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Zhejiang
Research Site
Hangzhou, Zhejiang, China
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Karen Atkin AstraZeneca
Study Chair: Louis Zhang AstraZeneca
Principal Investigator: Longyun Li Peking Union Medical College Hospital
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: MC MD, AstraZeneca China
ClinicalTrials.gov Identifier: NCT01000740     History of Changes
Other Study ID Numbers: 1839IL/0052 SubStudy
Study First Received: September 7, 2009
Last Updated: May 20, 2010
Health Authority: China: Ethics Committee

Keywords provided by AstraZeneca:
EAP
Long term survival (3 years)
Gefitinib
efficacy

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms

ClinicalTrials.gov processed this record on November 24, 2014